SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein

• Background:

  NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.

• Accession Number:

  YP_009725304.1

• Tag:

  His Tag at N-terminus

• Type:

  Recombinant Proteins

• Source:

  E. coli

• Field of Research:

  Infectious Disease, COVID-19

• Purity:

  >95% as determined by SDS-PAGE.

• Buffer:

  20 mM Tris, 250 mM NaCl, pH8.5 with glycerol

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Working aliquots should be stored at -70˚ C or lower. Avoid repeated freeze-thaw cycles.

• Calculated Molecular Weight:

  22-25 kDa

• Applications Notes:

  This recombinant protein can be used for WB. For research use only.

• Background Reference 01:

  Te Velthuis AJ, et al. Nucleic Acids Res. 2012. 40 (4) :1737-47.

• Background Reference 02:

  Edison Ong, et al. doi.org. 2020. 000141.

• Other Product Names:

  NSP8, nsp8, Non-structural protein 8, COVID-19

• Tested Applications:

  WB

• Species:

  SARS-CoV-2

• Physical Properties:

  Liquid

• CAS Number:

  9000-83-3